Profile of panitumumab as first-line treatment in patients with wild-type KRAS metastatic colorectal cancer

References

• SiegelRLMillerKDJemalACancer statistics, 2015CA Cancer J Clin20156552925559415
   PubMed Web of Science ®Google Scholar
• FerlayJSteliarova-FoucherELortet-TieulentJCancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012Eur J Cancer2013491374140323485231
   PubMed Web of Science ®Google Scholar
• RahibLSmithBDAizenbergRProjecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United StatesCancer Res2014742913292124840647
   PubMed Web of Science ®Google Scholar
• NishiharaRWuKLochheadPLong-term colorectal-cancer incidence and mortality after lower endoscopyN Engl J Med20133691095110524047059
   PubMed Web of Science ®Google Scholar
• De AngelisRSantMColemanMPCancer survival in Europe 1999–2007 by country and age: results of EUROCARE-5 – a population-based studyLancet Oncol201415233424314615
   PubMed Web of Science ®Google Scholar
• Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. Advanced Colorectal Cancer Meta-Analysis ProjectJ Clin Oncol1992108969031534121
   PubMed Web of Science ®Google Scholar
• KoopmanMAntoniniNFDoumaJSequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trialLancet200737013514217630036
   PubMed Web of Science ®Google Scholar
• HeinemannVvon WeikersthalLFDeckerTFOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trialLancet Oncol2014151065107525088940
   PubMed Web of Science ®Google Scholar
• VenookAPNiedzwieckiDLenzHJCALGB/SWOG 80405: phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC) [abstr LBA3]J Clin Oncol201432Suppl5s
   Google Scholar
• RobertsRBMinLWashingtonMKImportance of epidermal growth factor receptor signaling in establishment of adenomas and maintenance of carcinomas during intestinal tumorigenesisProc Natl Acad Sci U S A2002991521152611818567
   PubMed Web of Science ®Google Scholar
• HynesNELaneHAERBB receptors and cancer: the complexity of targeted inhibitorsNat Rev Cancer2005534135415864276
   PubMed Web of Science ®Google Scholar
• GuyPMPlatkoJVCantleyLCInsect cell-expressed p180erbB3 possesses an impaired tyrosine kinase activityProc Natl Acad Sci U S A199491813281368058768
   PubMed Web of Science ®Google Scholar
• GschwindAFischerOMUllrichAThe discovery of receptor tyrosine kinases: targets for cancer therapyNat Rev Cancer2004436137015122207
   PubMed Web of Science ®Google Scholar
• CohenSUshiroHStoscheckCA native 170,000 epidermal growth factor receptor-kinase complex from shed plasma membrane vesiclesJ Biol Chem1982257152315316276390
   PubMed Web of Science ®Google Scholar
• LiSSchmitzKRJeffreyPDStructural basis for inhibition of the epidermal growth factor receptor by cetuximabCancer Cell2005730131115837620
   PubMed Web of Science ®Google Scholar
• CitriAYardenYEGF-ERBB signalling: towards the systems levelNat Rev Mol Cell Biol2006750551616829981
   PubMed Web of Science ®Google Scholar
• LuettekeNCQiuTHFentonSETargeted inactivation of the EGF and amphiregulin genes reveals distinct roles for EGF receptor ligands in mouse mammary gland developmentDevelopment19991262739275010331984
   PubMed Web of Science ®Google Scholar
• LuettekeNCQiuTHPeifferRLTGF alpha deficiency results in hair follicle and eye abnormalities in targeted and waved-1 miceCell1993732632788477445
   PubMed Web of Science ®Google Scholar
• IwamotoRYamazakiSAsakuraMHeparin-binding EGF-like growth factor and ErbB signaling is essential for heart functionProc Natl Acad Sci U S A20031003221322612621152
   PubMed Web of Science ®Google Scholar
• SpanoJPFagardRSoriaJCEpidermal growth factor receptor signaling in colorectal cancer: preclinical data and therapeutic perspectivesAnn Oncol20051618919415668269
   PubMed Web of Science ®Google Scholar
• ChungKYShiaJKemenyNECetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistryJ Clin Oncol2005231803181015677699
   PubMed Web of Science ®Google Scholar
• AmadoRGWolfMPeetersMWild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancerJ Clin Oncol2008261626163418316791
   PubMed Web of Science ®Google Scholar
• ShiaJKlimstraDSLiAREpidermal growth factor receptor expression and gene amplification in colorectal carcinoma: an immunohistochemical and chromogenic in situ hybridization studyMod Pathol2005181350135615832190
   PubMed Web of Science ®Google Scholar
• PersoneniNFieuwsSPiessevauxHClinical usefulness of EGFR gene copy number as a predictive marker in colorectal cancer patients treated with cetuximab: a fluorescent in situ hybridization studyClin Cancer Res2008145869587618794099
   PubMed Web of Science ®Google Scholar
• CappuzzoFFinocchiaroGRossiEEGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patientsAnn Oncol20081971772317974556
   PubMed Web of Science ®Google Scholar
• Sartore-BianchiAMoroniMVeroneseSEpidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumabJ Clin Oncol2007253238324517664472
   PubMed Web of Science ®Google Scholar
• BaselgaJPfisterDCooperMRPhase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatinJ Clin Oncol20001890491410673534
   PubMed Web of Science ®Google Scholar
• Cetuximab FDA label2015 Available from: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Label_ApprovalHistory#labelinfoAccessed October 28, 2015
   Google Scholar
• YangXDJiaXCCorvalanJRDevelopment of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapyCrit Rev Oncol Hematol200138172311255078
   PubMed Web of Science ®Google Scholar
• YangXDJiaXCCorvalanJREradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapyCancer Res1999591236124310096554
   PubMed Web of Science ®Google Scholar
• Panitumumab FDA label2015 Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125147s200lbl.pdfAccessed October 28, 2015
   Google Scholar
• FoonKAYangXDWeinerLMPreclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibodyInt J Radiat Oncol Biol Phys20045898499014967460
   PubMed Web of Science ®Google Scholar
• RowinskyEKSchwartzGHGollobJASafety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancerJ Clin Oncol2004223003301515210739
   PubMed Web of Science ®Google Scholar
• WeinerLMBelldegrunASCrawfordJDose and schedule study of panitumumab monotherapy in patients with advanced solid malignanciesClin Cancer Res20081450250818223225
   PubMed Web of Science ®Google Scholar
• StephensonJJGregoryCBurrisHAn open-label clinical trial evaluating safety and pharmacokinetics of two dosing schedules of panitumumab in patients with solid tumorsClin Colorectal Cancer20098293719203894
   PubMed Web of Science ®Google Scholar
• DouillardJYSienaSCassidyJFinal results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancerAnn Oncol2014251346135524718886
   PubMed Web of Science ®Google Scholar
• SchwartzbergLSRiveraFKarthausMPEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancerJ Clin Oncol2014322240224724687833
   PubMed Web of Science ®Google Scholar
• Van CutsemESienaSHumbletYAn open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapyAnn Oncol2008191929817785764
   PubMed Web of Science ®Google Scholar
• KohneCHHofheinzRMineurLFirst-line panitumumab plus irinotecan/5-fluorouracil/leucovorin treatment in patients with metastatic colorectal cancerJ Cancer Res Clin Oncol2012138657221960318
   PubMed Web of Science ®Google Scholar
• SaltzLBLenzHJKindlerHLRandomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 studyJ Clin Oncol2007254557456117876013
   PubMed Web of Science ®Google Scholar
• HechtJRMitchellEChidiacTA randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancerJ Clin Oncol20092767268019114685
   PubMed Web of Science ®Google Scholar
• TolJKoopmanMCatsAChemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancerN Engl J Med200936056357219196673
   PubMed Web of Science ®Google Scholar
• de GramontAWatsonSEllisLMPragmatic issues in biomarker evaluation for targeted therapies in cancerNat Rev Clin Oncol20151219721225421275
   PubMed Web of Science ®Google Scholar
• JonkerDJO’CallaghanCJKarapetisCSCetuximab for the treatment of colorectal cancerN Engl J Med20073572040204818003960
   PubMed Web of Science ®Google Scholar
• KarapetisCSKhambata-FordSJonkerDJK-ras mutations and benefit from cetuximab in advanced colorectal cancerN Engl J Med20083591757176518946061
   PubMed Web of Science ®Google Scholar
• De RoockWJonkerDJDi NicolantonioFAssociation of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximabJAMA20103041812182020978259
   PubMed Web of Science ®Google Scholar
• MisaleSYaegerRHoborSEmergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancerNature201248653253622722830
   PubMed Web of Science ®Google Scholar
• SegelovEThavaneswaranSWaringPAbstract 32LBA. The AGITG ICECREAM Study: the Irinotecan Cetuximab Evaluation and Cetuximab Response Evaluation Amongst Patients with a G13D Mutation – analysis of outcomes in patients with refractory metastatic colorectal cancer harbouring the KRAS G13D mutationPaper presented at: European Cancer Congress2015Vienna, Austria
   Google Scholar
• DouillardJYOlinerKSSienaSPanitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancerN Engl J Med20133691023103424024839
   PubMed Web of Science ®Google Scholar
• MaughanTSAdamsRASmithCGAddition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trialLancet20113772103211421641636
   PubMed Web of Science ®Google Scholar
• PietrantonioFPetrelliFCoinuAPredictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysisEur J Cancer20155158759425673558
   PubMed Web of Science ®Google Scholar
• TherkildsenCBergmannTKHenrichsen-SchnackTThe predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: a systematic review and meta-analysisActa Oncol20145385286424666267
   PubMed Web of Science ®Google Scholar
• PrahalladASunCHuangSUnresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFRNature201248310011322281684
   PubMed Web of Science ®Google Scholar
• CremoliniCLoupakisFAntoniottiCFOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE studyLancet Oncol2015161306131526338525
   PubMed Web of Science ®Google Scholar
• Southwest Oncology GroupS1406 Phase II study of irinotecan and cetuximab with or without vemurafenib in BRAF mutant metastatic colorectal cancer Available from: https://www.clinicaltrials.gov/ct2/show/NCT02164916. NLM identifier: NCT02164916Accessed October 28, 2015
   Google Scholar
• Novartis PharmaceuticalsStudy of LGX818 and cetuximab or LGX818, BYL719, and cetuximab in BRAF mutant metastatic colorectal cancer Available from: https://www.clinicaltrials.gov/ct2/show/NCT01719380. NLM identifier: NCT01719380Accessed October 28, 2015
   Google Scholar
• SchellensJHVan GeelRBendellJCFinal biomarker analysis of the phase I study of the selective BRAF V600 inhibitor encorafenib (LGX818) combined with cetuximab with or without the α-specific PI3K inhibitor alpelisib (BYL719) in patients with advanced BRAF-mutant colorectal cancerPaper presented at: AACR 106th Annual MeetingApril 18–22, 2015Philadelphia, PA Abst #CT136
   Google Scholar
• RiveraFKarthausMHechtJRFirst-line treatment with modified FOLFOX6 (mFOLFOX6) + panitumumab (pmab) or bevacizumab (bev) in wild-type (WT) RAS metastatic colorectal carcinoma (mCRC): tumor response outcomes beyond RECIST [abstr 660]J Clin Oncol201533Suppl 3
   Google Scholar
• Van CutsemELenzHJKohneCHFluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in col-orectal cancerJ Clin Oncol20153369270025605843
   PubMed Web of Science ®Google Scholar
• AllegraCJRumbleRBHamiltonSRExtended RAS gene mutation testing in metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update 2015J Clin Oncol Epub1052015
   Google Scholar
• Garrido-LagunaIHongDSJankuFKRASness and PIK3CAness in patients with advanced colorectal cancer: outcome after treatment with early-phase trials with targeted pathway inhibitorsPLoS One20127e3803322675430
   PubMed Web of Science ®Google Scholar
• SamuelsYDiazLAJrSchmidt-KittlerOMutant PIK3CA promotes cell growth and invasion of human cancer cellsCancer Cell2005756157315950905
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas NetworkComprehensive molecular characterization of human colon and rectal cancerNature201248733033722810696
   PubMed Web of Science ®Google Scholar
• De RoockWClaesBBernasconiDEffects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysisLancet Oncol20101175376220619739
   PubMed Web of Science ®Google Scholar
• KarapetisCSJonkerDDaneshmandMPIK3CA, BRAF, and PTEN status and benefit from cetuximab in the treatment of advanced colorectal cancer – results from NCIC CTG/AGITG CO.17Clin Cancer Res20142074475324218517
   PubMed Web of Science ®Google Scholar
• GherardiEBirchmeierWBirchmeierCTargeting MET in cancer: rationale and progressNat Rev Cancer2012128910322270953
   PubMed Web of Science ®Google Scholar
• BardelliACorsoSBertottiAAmplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancerCancer Discov2013365867323729478
   PubMed Web of Science ®Google Scholar
• PriceTJPeetersMKimTWPanitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 studyLancet Oncol20141556957924739896
   PubMed Web of Science ®Google Scholar
• WadlowRCHezelAFAbramsTAPanitumumab in patients with KRAS wild-type colorectal cancer after progression on cetuximabOncologist2012171422210091
   PubMed Web of Science ®Google Scholar
• MontagutCDalmasesABellosilloBIdentification of a mutation in the extracellular domain of the epidermal growth factor receptor conferring cetuximab resistance in colorectal cancerNat Med20121822122322270724
   PubMed Web of Science ®Google Scholar
• ArenaSBellosilloBSiravegnaGEmergence of multiple EGFR extracellular mutations during cetuximab treatment in colorectal cancerClin Cancer Res20152192157216625623215
   PubMed Web of Science ®Google Scholar
• PriceTJNewhallKPeetersMPrevalence and outcomes of patients (pts) with EGFR S492R ectodomain mutations in ASPECCT: panitumumab (pmab) vs. cetuximab (cmab) in pts with chemorefractory wild-type KRAS exon 2 metastatic colorectal cancer (mCRC)J Clin Oncol201533Suppl abstr e14623. ASCO Annual Meeting Proceedings
   Google Scholar
• LaneDPCancer. p53, guardian of the genomeNature199235815161614522
   PubMed Web of Science ®Google Scholar
• Oden-GangloffADi FioreFBibeauFTP53 mutations predict disease control in metastatic colorectal cancer treated with cetuximab-based chemotherapyBr J Cancer20091001330133519367287
   PubMed Web of Science ®Google Scholar
• PeetersMOlinerKSParkerAMassively parallel tumor multigene sequencing to evaluate response to panitumumab in a random-ized phase III study of metastatic colorectal cancerClin Cancer Res2013191902191223325582
   PubMed Web of Science ®Google Scholar
• KavuriSMJainNGalimiFHER2 activating mutations are targets for colorectal cancer treatmentCancer Discov2015583284126243863
   PubMed Web of Science ®Google Scholar
• BertottiAPappEJonesSThe genomic landscape of response to EGFR blockade in colorectal cancerNature201552626326726416732
   PubMed Web of Science ®Google Scholar
• LacoutureMEMitchellEPPiperdiBSkin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-Emptive Skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancerJ Clin Oncol2010281351135720142600
   PubMed Web of Science ®Google Scholar
• TejparSLenzHJKohneCHEffect of KRAS and NRAS mutations on treatment outcomes in patients with metastatic colorectal cancer (mCRC) treated first-line with cetuximab plus FOLFOX4: new results from the OPUS study [abstr LBA444]J Clin Oncol201432Suppl 3
   Google Scholar
• MaoCWuXYYangZYConcordant analysis of KRAS, BRAF, PIK3CA mutations, and PTEN expression between primary colorectal cancer and matched metastasesSci Rep20155806525639985
   PubMed Web of Science ®Google Scholar
• IsellaCTerrasiABellomoSEStromal contribution to the colorectal cancer transcriptomeNat Genet20154731231925706627
   PubMed Web of Science ®Google Scholar